S
EVERAL CLINICAL PRACTICE GUIDElines for type 2 diabetes are now available. All advocate a hemoglobin A 1c level of less than 7%, and at least 1 organization has adopted a target of 6.5%. [1] [2] [3] Despite the number of agents to choose from, Inzucchi 4 notes that the only ones evaluated in randomized controlled trials with regard to clinically important outcomes are insulin, metformin, and the sulfonylureas. [5] [6] [7] Two important clinical trials have demonstrated that more aggressive glycemic control in type 2 diabetic patients reduced microvascular complications. Questions remain about the effect of all the oral agents and insulin on reducing macrovascular complications. 6, 7 Primary care physicians provide much of the care for patients with type 2 diabetes. 8 Although this article discusses primarily drug treatment, education on self-management, nutrition, and exercise is essential to help patients achieve glycemic control. Selfmanagement training is effective in type 2 diabetes and should be recommended for all patients. 9 Recommendations for the use of oral agents for each clinical situation are based on the best evidence available and accepted clinical guidelines. Informed decision making about therapy, however, must involve the patient and include a clear explanation of therapeuticchoice rationale, an assessment of his or her understanding, preferences, and barriers to care, and a discussion of the risks and benefits of each therapy. [10] [11] [12] An active patient-physician partnership facilitates treatment of this complex, multifaceted disease. 13 The TABLE provides a brief summary of the available oral agents and their relative costs. The BOX provides additional resources.
CLINICAL CONTEXT Patient 1
A moderately obese 49-year-old woman (body mass index, 29 kg/m 2 ) complains of increased thirst, polyuria, and fatigue. Her family history is pertinent for diabetes in her mother and an older brother. A random plasma glucose serum test shows a level of 480 mg/dL (26.6 mmol/L). Her serum electrolyte and anion gap levels are normal.
At this visit, the patient meets American Diabetes Association criteria for having diabetes.
14 Given her symptoms and high blood glucose level, the question is whether to start an oral agent or insulin therapy. Guidelines are not prescriptive regarding the choice of the initial agent. [1] [2] [3] 15 One consideration in deciding whether to initiate insulin therapy or an oral agent is glucose toxicity. 16, 17 High levels of glucose are toxic to pancreatic beta cells, impairing insulin secretion in the face of relative insulin deficiency. Although not studied in a randomized controlled trial, initial treatment with insulin has been suggested to allow more rapid control of plasma glucose, recovery of beta cell function, and better subsequent response to oral agents. 17, 18 Additionally, insulin dosage can be adjusted quickly, facilitating more rapid control of hyperglycemia and associated symptoms.
15-17 Once a stable target glucose level has been achieved, the patient may be able to begin receiving an oral agent. However, insulin therapy does require immediate patient education on injection techniques, use of a home glucose meter, and identification and treatment of hypoglycemic reactions. If available locally, certified diabetes nurse educators can be particularly helpful in this process. Deciding whether to start insulin therapy also requires assessment of the patient's understanding and wishes. 10 When the patient is switched to an oral agent or an oral agent is used as initial therapy, guidelines suggest that either a sulfonylurea or metformin agent is appropriate. However, given that this patient is moderately obese, metformin would be the recommended initial agent. 4, 7, 15 It tends to promote weight loss and is equally effective in lowering hemoglobin A 1c compared with sulfonylurea and thiazolidinedione (TZD) agents. 4 Given her degree of hyperglycemia, this patient may eventually need 2 oral agents to achieve adequate control.
Patient 2
A 57-year-old man with type 2 diabetes treated for 9 years is currently receiving glyburide at a dosage of 10 mg/d. His hemoglobin A 1c level a week ago was 8.5%. You suggest adding metformin, but the patient wonders why he cannot increase his glyburide dose because his hemoglobin A 1c level was always controlled well by this medication and he has been told that 10 mg is only half the maximal dose.
Although daily doses of up to 20 mg of glyburide and 40 mg of glipizide are approved and can be used, data have clearly shown that, above 10 to 12 mg/d, the additional gain in glycemic control is marginal. 19 In addition, the failure rate of sulfonylurea therapy is 5% yearly, and this patient has been receiving glyburide therapy for 9 years. 4, 6, 7, 15 Thus, increasing his sulfonylurea dose is highly unlikely to help him reach the target level of hemoglobin A 1c . Likewise, switching to another single oral agent such as metformin, TZD, or meglitinide or another nonsulfonylurea secretagogue is unlikely to lead to adequate glycemic control, given the duration of his diabetes. Therefore, addition of another agent should be considered. The United Kingdom Prospective Diabetes Study (UKPDS) and other trials found that adding metformin to sulfonylurea therapy lowered hemoglobin A 1c levels. 4, 7, 20, 21 The UKPDS, however, found an unexpected increase in diabetes-related mortality with this combination, although when all patients who were actually treated with metformin according to protocol analysis were investigated, a 19% reduction in diabetes-related end points was observed. 7, 22 Another option is to add a TZD; this combination has also shown substantial reductions in hemoglobin A 1c levels. 4 Although no definite evidence exists of severe hepatotoxicity with rosiglitazone and pioglitazone, frequent monitoring of liver enzymes is still required because of troglitazone's association with hepatotoxicity.
Patient 3
A 55-year-old woman was diagnosed with diabetes almost 10 years ago and is Before embarking on a discussion about therapy, the physician should first acknowledge and discuss the patient's concerns about insulin therapy. Regarding drug treatment, will any of the remaining available oral agents lower hemoglobin A 1c levels in this patient? Because of its relative decreased efficacy in lowering hemoglobin A 1c levels, acarbose would not be a good therapeutic option. 4, 23 The meglitinides are insulin secretagogues and therefore would not be effective in a patient already receiving a sulfonylurea agent. 4 The only feasible additional oral agent to use would be rosiglitazone or pioglitazone, both of which are approved for use in combination with metformin or a sulfonylurea agent. A recent study found that 43% of patients receiving triple oral therapy (sulfonylurea, metformin, and troglitazone) achieved a target hemoglobin A 1c value (Ͻ8%) compared with only 6% of patients taking the metforminsulfonylurea combination. 24 Regardless of approach, the main goal for this relatively young patient remains optimal glycemic control with a hemoglobin A 1c level below 6.5%. Insulin therapy is another reasonable option and is less expensive than adding a TZD (Table) . 1, 4, 15 If rosiglitazone or pioglitazone is added, the full effect of the TZD therapy may not be apparent for 4 to 12 weeks, but a hemoglobin A 1c level should be assessed at 3 months. Although this patient is resistant to starting insulin therapy, better glycemic control through insulin therapy in the UKPDS 6 and the Kumomato Trial 5 led to a reduction in microvascular complications. If the target hemoglobin A 1c level is not attained with the addition of a TZD, then insulin therapy is the best option. Many patients will eventually require insulin therapy for adequate glycemic control. In the UKPDS, for example, approximately 10% of patients initially assigned to receive a sulfonylurea agent had to start receiving insulin therapy during the trial. 6 Talking to the patient may help her overcome her reluctance to start insulin therapy.
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Patient 4
A 72-year-old man with a history of hypertension, myocardial infarction, and New York Heart Association class II congestive heart failure comes to the clinic for a routine follow-up visit. At his last visit 6 months ago, his random blood glucose level was 180 mg/dL (10.0 mmol/L). He was not subsequently tested for a fasting blood glucose level but was encouraged to lose weight and maintain a proper diet. He now complains of having had polyuria and constant thirst for the past 2 months. His random blood glucose level is tested in your office and is 260 mg/dL (14.4 mmol/L). His creatinine level was 1.7 mg/dL (129.63 µmol/L) 6 months ago. The patient weighs 83.3 kg. He is receiving spironolactone, furosemide for his hypertension, and an angiotensin-converting enzyme inhibitor for congestive heart failure. What are your therapeutic options?
Although determining a fasting glucose level and a baseline hemoglobin A 1c level will be helpful, the patient now has symptomatic diabetes and warrants pharmacologic treatment. Although it appears that diet did not control his blood glucose level, reinforcing the importance of diet and lifestyle should still be attempted.
26 Evidence exists that suggests consulting a nutritionist or diabetes educator improves glycemic control. 27, 28 Regarding drug therapy, there are several important issues to consider for this older diabetic patient outcome data for elderly diabetics exist. However, several studies have found that lower hemoglobin A 1c levels are associated with lower costs for patients in all age groups, especially those with cardiovascular disease, [29] [30] [31] and better control of diabetes improves the quality of life for older diabetic patients. [32] [33] [34] Second, what are the appropriate oral agents for this patient? Given his underlying cardiovascular disease, metformin would be an ideal agent, but his history of congestive heart failure and elevated serum creatinine levels are absolute contraindications. Remaining agents to lower blood glucose levels are a sulfonylurea, a rapidacting secretagogue, or a TZD. A major concern about starting sulfonylurea treatment in older patients is hypoglycemia that can be profound and prolonged because of the long half-life of the secondgeneration agents. If a long-acting sulfonylurea is chosen, the lowest possible starting dose (eg, 2.5 mg of glipizide) should be initiated and the patient fully educated about hypoglycemic reactions and treatment. 4, 34 His mild renal insufficiency also places him at increased risk for hypoglycemia. If hypoglycemia is a major concern related to other underlying health issues (eg, the patient is at significant risk for falls or lives alone), a rapid-acting secretagogue taken with meals may be safer because of its shorter half-life. 4 The disadvantage is the frequent dosing schedule required with these agents. Acarbose could be tried, but the magnitude of glucose-level reduction is less than that with other agents, the adverse gastrointestinal effects may be difficult for this older patient with congestive heart failure, and again the drug must be taken several times a day. 4 A TZD may be prescribed but should be used only cautiously in this patient with class II congestive heart failure. Because of their propensity to expand plasma volume, TZDs are clearly contraindicated for patients with class III and IV congestive heart failure. Therefore, for this patient an oral agent may not be the best treatment and in fact may increase the risk of adverse events because of his multiple comorbidities. Despite the mild degree of hyperglycemia, insulin may be the best choice as an initial agent in this patient. It has several advantages: flexibility with regard to dose and dosing adjustments and multiple preparations that allow physicians to tailor a treatment regimen that best meets the needs and goals of the patient.
CONCLUSIONS
Decisions about treatment with oral agents require a number of important considerations, including drug efficacy and adverse effects, strength of evidence, patient preferences, cost, and effective use of nonpharmacologic therapies such as diet and exercise. Patient involvement in self-management is critical to successful glycemic control, and all therapeutic choices must involve a comprehensive dialogue and negotiation between patient and physician. Organizations to obtain resources for caring for diabetic patients are provided in the Box. For the majority of patients, the overarching goal is to lower the hemoglobin A 1c level to as close to normal and as safely as possible.
